HILLHURST BIOPHARMACEUTICALS RECEIVES NIH HEAL INITIATIVE AWARD FOR DEVELOPMENT OF HBI-201 IN PAIN

SAN DIEGO, Nov. 7, 2023 /PRNewswire/ — Hillhurst Biopharmaceuticals, Inc. (“Hillhurst”), a clinical-stage biopharmaceutical company focused on developing liquid drug products containing therapeutic gases, today announced the award of an up to $5 million HEAL (Helping to End Addiction…

Click here to view original post